Literature DB >> 25637190

Rescue of an in vitro neuron phenotype identified in Niemann-Pick disease, type C1 induced pluripotent stem cell-derived neurons by modulating the WNT pathway and calcium signaling.

Anastasia G Efthymiou1, Joe Steiner1, William J Pavan1, Stephen Wincovitch1, Denise M Larson1, Forbes D Porter1, Mahendra S Rao1, Nasir Malik2.   

Abstract

Niemann-Pick disease, type C1 (NPC1) is a familial disorder that has devastating consequences on postnatal development with multisystem effects, including neurodegeneration. There is no Food and Drug Administration-approved treatment option for NPC1; however, several potentially therapeutic compounds have been identified in assays using yeast, rodent models, and NPC1 human fibroblasts. Although these discoveries were made in fibroblasts from NPC1 subjects and were in some instances validated in animal models of the disease, testing these drugs on a cell type more relevant for NPC1 neurological disease would greatly facilitate both study of the disease and identification of more relevant therapeutic compounds. Toward this goal, we have generated an induced pluripotent stem cell line from a subject homozygous for the most frequent NPC1 mutation (p.I1061T) and subsequently created a stable line of neural stem cells (NSCs). These NSCs were then used to create neurons as an appropriate disease model. NPC1 neurons display a premature cell death phenotype, and gene expression analysis of these cells suggests dysfunction of important signaling pathways, including calcium and WNT. The clear readout from these cells makes them ideal candidates for high-throughput screening and will be a valuable tool to better understand the development of NPC1 in neural cells, as well as to develop better therapeutic options for NPC1. ©AlphaMed Press.

Entities:  

Keywords:  Calcium signaling; Disease modeling; Neural stem cells; Niemann-pick disease, type C1; WNT signaling

Mesh:

Substances:

Year:  2015        PMID: 25637190      PMCID: PMC4339848          DOI: 10.5966/sctm.2014-0127

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  43 in total

1.  Efficient generation of astrocytes from human pluripotent stem cells in defined conditions.

Authors:  Atossa Shaltouki; Jun Peng; Qiuyue Liu; Mahendra S Rao; Xianmin Zeng
Journal:  Stem Cells       Date:  2013-05       Impact factor: 6.277

2.  GSK3 temporally regulates neurogenin 2 proneural activity in the neocortex.

Authors:  Saiqun Li; Pierre Mattar; Dawn Zinyk; Kulwant Singh; Chandra-Prakash Chaturvedi; Christopher Kovach; Rajiv Dixit; Deborah M Kurrasch; Yong-Chao Ma; Jennifer A Chan; Valerie Wallace; F Jeffrey Dilworth; Marjorie Brand; Carol Schuurmans
Journal:  J Neurosci       Date:  2012-06-06       Impact factor: 6.167

3.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid.

Authors:  Benny Liu; Charina M Ramirez; Anna M Miller; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2009-11-18       Impact factor: 5.922

4.  Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc1-/- mice.

Authors:  Min Zhang; Diana Strnatka; Carolyn Donohue; Janice L Hallows; Inez Vincent; Robert P Erickson
Journal:  J Neurosci Res       Date:  2008-10       Impact factor: 4.164

5.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

Review 6.  Molecular mechanisms of curcumin action: signal transduction.

Authors:  Adeeb Shehzad; Young Sup Lee
Journal:  Biofactors       Date:  2013-01-10       Impact factor: 6.113

Review 7.  The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.

Authors:  Saadet Inan; Huafeng Wei
Journal:  Anesth Analg       Date:  2010-09-22       Impact factor: 6.627

8.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

Review 9.  Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases.

Authors:  Vittorio Calabrese; Carolin Cornelius; Cesare Mancuso; Eugenio Barone; Stella Calafato; Timothy Bates; Enrico Rizzarelli; Albena T Dinkova Kostova
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells.

Authors:  Dorothea Maetzel; Sovan Sarkar; Haoyi Wang; Lina Abi-Mosleh; Ping Xu; Albert W Cheng; Qing Gao; Maisam Mitalipova; Rudolf Jaenisch
Journal:  Stem Cell Reports       Date:  2014-05-15       Impact factor: 7.765

View more
  22 in total

Review 1.  Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond.

Authors:  N J Schork; K Nazor
Journal:  Adv Genet       Date:  2017-07-25       Impact factor: 1.944

Review 2.  Modeling neuronopathic storage diseases with patient-derived culture systems.

Authors:  Friederike Zunke; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2019-02-19       Impact factor: 5.996

Review 3.  Disease models for the development of therapies for lysosomal storage diseases.

Authors:  Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger
Journal:  Ann N Y Acad Sci       Date:  2016-05-04       Impact factor: 5.691

Review 4.  Lysosome and endoplasmic reticulum quality control pathways in Niemann-Pick type C disease.

Authors:  Mark L Schultz; Kelsey L Krus; Andrew P Lieberman
Journal:  Brain Res       Date:  2016-03-26       Impact factor: 3.252

Review 5.  Human induced pluripotent stem cells for monogenic disease modelling and therapy.

Authors:  Paola Spitalieri; Valentina Rosa Talarico; Michela Murdocca; Giuseppe Novelli; Federica Sangiuolo
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

6.  Acidic Ca2+ stores in neurodegeneration.

Authors:  Emyr Lloyd-Evans
Journal:  Messenger (Los Angel)       Date:  2016-06-01

Review 7.  Induced pluripotent stem cell models of lysosomal storage disorders.

Authors:  Daniel K Borger; Benjamin McMahon; Tamanna Roshan Lal; Jenny Serra-Vinardell; Elma Aflaki; Ellen Sidransky
Journal:  Dis Model Mech       Date:  2017-06-01       Impact factor: 5.758

8.  Activation of PKC triggers rescue of NPC1 patient specific iPSC derived glial cells from gliosis.

Authors:  Franziska Peter; Sebastian Rost; Arndt Rolfs; Moritz J Frech
Journal:  Orphanet J Rare Dis       Date:  2017-08-25       Impact factor: 4.123

9.  Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.

Authors:  Olga Momcilovic; Renuka Sivapatham; Tal Ronnen Oron; Morten Meyer; Sean Mooney; Mahendra S Rao; Xianmin Zeng
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

Review 10.  Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders.

Authors:  Serena Barral; Manju A Kurian
Journal:  Front Mol Neurosci       Date:  2016-09-06       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.